Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome

Stanford University120 enrolled

Overview

The investigators are testing treatment with low-dose naltrexone (LDN) for symptom relief of complex regional pain syndrome (CRPS). Study participants will be randomly assigned to receive either LDN or placebo for a period of several weeks. During this period participants will be asked to attend either in-person or virtual study visits and complete questionnaires.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

120

Conditions

Complex Regional Pain Syndrome

Interventions

LDNDRUG

PlaceboDRUG

Sugar pill

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Upper and/or lower extremity CRPS * On stable treatment for 1 month * CRPS for at least 1 year * Meet the Budapest criteria for CRPS at time of the study. Exclusion Criteria: * Any known allergy to naltrexone or naloxone * Use of prescription opioid analgesics or illegal opioid use * Current or planned pregnancy.

Locations (1)

Stanford University

Palo Alto, California, United States

RECRUITING

Outcomes

Primary Outcomes

Changes in pain severity

Daily pain reports on a 0-10 numerical rating scale for pain, where 0=no pain and 10=pain as bad as you can imagine

Time frame: Approximately 4 weeks after conclusion of treatment.

Central Contacts

Birute Gedrimaite

CONTACT

(650) 497-0485 birute@stanford.edu

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.